Prevention of HIV/AIDS with opioid substitution therapy: An exploratory study among injecting drug users in a tertiary health-care center of Kolkata

Author(s):  
Manika Pal ◽  
Madhumita Dobe ◽  
Asish Mukherjee ◽  
Dipendra Goswami
2021 ◽  
Vol 20 (3) ◽  
pp. 63-70
Author(s):  
M.A. Shylava ◽  
◽  
A.V. Abramovich ◽  

Objectives. To identify the medico-social and epidemiological peculiarities of HIV-infected people injecting drugs (PWID) at the stage of joining the opioid substitution therapy (OST) program, who adopted it in 2019 in the city of Minsk. Material and methods. The data of the primary accounting documentation of the Health Care Institution «City Clinical Narcological Dispensary» and the Health Care Institution «City Clinical Infectious Diseases Hospital» of PWID HIV-infected patients were analyzed on joining the opioid substitution therapy program who adopted it in 2019 in the city of Minsk (n=91). Results. It has been found that the largest proportion of the OST program participants constituted males (73.63%) aged 36 years and older (73.62%); 64.84% of them were convicted more than 3 times, 83.52% were not officially married, 64.84% were officially unemployed. The median experience of using opioid drugs made up 21 (19-24) years. Almost ½ (46.15%) of HIV-infected drug users were members of OST program for 3 (1-5) years in 2019. Most of the OST program participants (83.52%) had up to 3 periods without drug use, while in 54.95% of them these breaks were due to serving a sentence, and in 21.98% because of undergoing rehabilitation. Lifestyle changes and socialization in society were authentically the most significant reasons and motives for the participation of PWID HIV-infected persons in the OST program in Minsk (p<0.05). The analysis of the comorbidity rate showed that all the participants in the studied group were infected with viral hepatitis C, 6.59% - with hepatitis B against the background of hepatitis C virus (HCV), and 1.01% - with hepatitis D. Conclusions. The revealed medical, social and epidemiological features of HIV-infected PWID persons at the stage of joining the opioid substitution therapy program will make it possible to increase the efficiency of providing medical care to opioid drug users with HIV infection and parenteral viral hepatites and extend the coverage of the studied contingent by this program.


2019 ◽  
Vol 71 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Juan Macías ◽  
Luis E. Morano ◽  
Francisco Téllez ◽  
Rafael Granados ◽  
Antonio Rivero-Juárez ◽  
...  

2016 ◽  
Vol 10s1 ◽  
pp. SART.S34553 ◽  
Author(s):  
Lisa E. Graves ◽  
Suzanne Turner ◽  
Maya Nader ◽  
Sucheta Sinha

Introduction Despite research demonstrating the safety and benefit of breastfeeding in opioid substitution therapy, few women in treatment breastfeed. Understanding the factors contributing to the choices women on opioid substitution therapy make about infant feeding is important. Objectives The aim of this study was to better understand and support infant feeding choices and breastfeeding experiences in women on opioid substitution therapy. Methods A systematic review was conducted on five databases: (1) Ovid MEDLINE(R) without revisions, (2) Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, (3) EMBASE, (4) CINAHL, and (5) FRANCIS. From 1081 articles, 46 articles were reviewed. Results The literature supports breastfeeding as an appropriate and safe option for women on opioid substitution treatment. Breastfeeding and rooming-in reduce neonatal abstinence. Women face barriers to breastfeeding due to societal stigma and the lack of patient and health-care provider education. Conclusions Efforts are needed to increase the knowledge that women and health-care professionals have about the safety and benefits of breastfeeding.


2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Heino Stöver ◽  
Daniela Jamin ◽  
Ingo Ilja Michels ◽  
Bärbel Knorr ◽  
Karlheinz Keppler ◽  
...  

Abstract Background The above-average proportion of people with opioid use disorder living in prisons is a worldwide reality, and the need to treat these people was recognized internationally more than 20 years ago. Studies have shown that substitution therapies are best suited to treat opioid use disorder and reduce the risk of HIV and hepatitis C transmission and overdose. However, huge health inequalities exist in and outside of prison due to the different implementation of opioid substitution therapy (OST). People living in prisons are entitled to the best possible health care. This is established by the Universal Declaration of Human Rights and by the International Convention on Economic, Social and Cultural Rights. Solely the imprisonment, and not the loss of fundamental human rights, constitutes the punishment. Methods A qualitative literature search using PubMed and Google Scholar was performed in order to identify relevant publications. Results This review shows the inequality in availability of opioid substitution therapy for people living in prison compared with people outside of prison in Germany. It also gives possible reasons and evidence for this inequality, showing that continuing or initiating OST in prison is more beneficial for the health of people living in prison than abstinence-oriented treatment only. Conclusion It is important that drug use disorder is treated as a serious illness also in prison. Joint efforts are needed to provide people living in prison with the best possible treatment and to minimize the adverse effects of drug use. Therefore, with laws, policies, and programs that conform to international human rights standards, each state must ensure that people living in prison receive the same health care as people outside of prison.


Sign in / Sign up

Export Citation Format

Share Document